BioSpace News Archive

Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) approved two outpatient Emergency Investigational New Drug Applications (eINDs) for treating mild to moderate respiratory distress due to COVID-19. Organicell’s first patient approved for the eIND experienced moderate chest discomfort ac

AMAG Pharmaceuticals, Inc. reported unaudited consolidated financial results for the second quarter ended June 30, 2020.

TAE Life Sciences, a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy solutions, announced that Bruce Bauer, Chief Executive Officer, will present a corporate overview at the Summer 2020 Private Company Showcase, hosted by Solebury Trout, on August 10, 2020.

Pulpdent is a family-owned medical device company that has been serving dentists and their patients for 73 years.

Baudax Bio, Inc., a pharmaceutical company focused on therapeutics for acute care settings, announced that the Centers for Medicare and Medicaid Services established a new permanent J-code for ANJESO injection facilitating reimbursement in the hospital outpatient, ambulatory surgery center and physician office settings of care.

Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL), an SEC fully-reporting, growth-oriented manufacturing and marketing company focused on employing FDA-approved Metered Dose Inhaler (MDI) technology to deliver aerosolized cannabinoids, such as CBD, CBG, and CBN, announces its relationship with Ezzey Digital Marketing Agency to launch its new proprietary aerosol inhaler and lifestyle brand to be called nhāler. RTSL digital infrastructure built

- Reported responses in multiple solid tumor types during ASCO with updates at upcoming congresses in Q4 - - Continued progress toward launch of ADP-A2M4 for sarcoma in the US in 2022 with ongoing enrollment of patients in SPEARHEAD-1 - - Granted access to PRIority MEdicines (PRIME) regulatory support by the European Medicines Agency for ADP-A2M4 for the treatment of synovial sarcoma - - Completed public offering with net proceeds of approximately $244m; guidance confirmed: funded into 2022

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday August 10, 2020 at 8:30 AM ET to discuss results for the second quarter of 2020 and provide a business outlook for the remainder of the year. Michael S. Weiss, Executive Chairman and Chief Executive Officer, will host the call.

Nordic Nanovector ASA announces that, following a planned interim analysis of the PARADIGME Phase 2b pivotal trial of Betalutin® in patients with relapsed/refractory follicular lymphoma, the Independent Review Committee has recommended Nordic Nanovector to focus on one dosage arm to completion.

Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, will convene an extraordinary general meeting on September 1, 2020 at 10 am Helsinki time to elect Cynthia Schwalm as a new board member.